eloralintide/tirzepatide (EloraTZP) / Eli Lilly - LARVOL DELTA

Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes (Eli Lilly Press Release) - "At 48 weeks, all combinations of EloraTZP met the primary and secondary endpoints, delivering substantial weight loss and A1C reduction. Results from the trial were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy...Eloralintide alone reduced body weight by up to an average of 28.6 lbs (12.3%) and A1C by up to an average of 1.4%, while tirzepatide 15 mg reduced body weight by an average of 34.4 lbs (14.8%) and A1C by 2.4%. Participants taking EloraTZP lost up to an average of 54.1 lbs (23.3%) and lowered their A1C by up to an average of 2.9% at 48 weeks, beyond what either medicine achieved alone....Lilly plans to initiate Phase 3 studies of an EloraTZP co-formulation product by the end of 2026 using an optimized escalation schedule."

New P3 trial • P2b data • Obesity • Type 2 Diabetes Mellitus